Novo Nordisk’s (NYSE:NVO) Obesity Drug Potentially Linked to Eye Disorder

TIPRANKS07-04

Shares of Novo Nordisk (NYSE:NVO) are down in today’s trading after a small study published in the medical journal JAMA suggested that there is a l...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2448438534?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-04 00:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2448438534","market":"us","top_or_hot":-1,"title":"Novo Nordisk’s (NYSE:NVO) Obesity Drug Potentially Linked to Eye Disorder","media":"TIPRANKS","content":"<div>\n<p>Shares of Novo Nordisk (NYSE:NVO) are down in today’s trading after a small study published in the medical journal JAMA suggested that there is a l...</p>\n\n<a href=\"https://www.tipranks.com/news/novo-nordisks-nysenvo-obesity-drug-potentially-linked-to-eye-disorder?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n","source":"tipranks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk’s (NYSE:NVO) Obesity Drug Potentially Linked to Eye Disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk’s (NYSE:NVO) Obesity Drug Potentially Linked to Eye Disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-04 00:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/novo-nordisks-nysenvo-obesity-drug-potentially-linked-to-eye-disorder?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Novo Nordisk (NYSE:NVO) are down in today’s trading after a small study published in the medical journal JAMA suggested that there is a l...</p>\n\n<a href=\"https://www.tipranks.com/news/novo-nordisks-nysenvo-obesity-drug-potentially-linked-to-eye-disorder?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.tipranks.com/news/novo-nordisks-nysenvo-obesity-drug-potentially-linked-to-eye-disorder?utm_source=itigerup.com&utm_medium=referral","article_id":"2448438534","we_media_id":null,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/novo-nordisks-nysenvo-obesity-drug-potentially-linked-to-eye-disorder?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2448438534","pubTimestamp":1720024982,"sourceInfo":{"source_id":"tipranks_highlight","name":"Tipranks"},"weMediaInfo":null,"summary":"Shares of Novo Nordisk (NYSE:NVO) are down in today’s trading after a small study published in the medical journal JAMA suggested that there is a l...","collect":0,"end_time":0,"defaultTopTitle":"tipranks.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","NVO":"诺和诺德","BK4007":"制药","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4532":"文艺复兴科技持仓","NYSE":"纽交所","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4585":"ETF&股票定投概念"},"translate_title":"诺和诺德（纽约证券交易所股票代码：NVO）的肥胖药物可能与眼病有关","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1,"NYSE":1},"content_text":"Shares of Novo Nordisk (NYSE:NVO) are down in today’s trading after a small study published in the medical journal JAMA suggested that there is a l...","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2448438534"}